The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain reassures on AstraZeneca after advising under-30s take other vaccines

Thu, 08th Apr 2021 19:06

* Officials stand by AstraZeneca after guidance change

* Some fret that messaging will lead people to reject shot

* Minister says enough Pfizer, Moderna shots for younger
adults

By Alistair Smout

LONDON, April 8 (Reuters) - British officials and ministers
sought to shore up confidence in AstraZeneca's COVID-19
vaccine on Thursday, saying advice that most people under 30
should be offered alternative shots was not unusual and would
not impact the pace of rollout.

A pharmacist whose brother died from a brain blood clot
linked to the AstraZeneca shot was among those calling for
people to keep getting it, saying the doses would save lives.

Officials said the suggestion that under-30s should be
offered an alternative did not reflect any serious safety
concerns, just a "vanishingly" rare possible side effect.

Anthony Harnden, Deputy Chairman of the Joint Committee on
Vaccination and Immunisation (JCVI) which issued the new advice,
said such suggestions were not unusual, pointing out that people
of different ages already got different flu shots in Britain.

"This isn't unusual. So this is not undermining what the
regulators are saying. The regulators are saying this vaccine is
suitable for all age groups but it's up to the individual
countries to decide how best to deploy those vaccines," he told
Reuters in an interview.

While Britain's MHRA medicine regulator did not place age
restrictions on the use of the AstraZeneca shot, some saw the
JCVI's advice about under-30s, made in the same briefing, as
mixed messaging.

Conservative lawmaker Iain Duncan Smith said the
announcement was "ridiculous" and that there was "the dangerous
potential" that people would refuse to have AstraZeneca's shot.

Health minister Matt Hancock defended the move, saying the
transparency over possible side effects, even very rare ones,
should bolster confidence in the system.

Britain has continued to use its homegrown AstraZeneca
vaccine since it became the first country to start rolling it
out at the start of January. Some countries in Europe, including
France, restricted its use in older people initially, citing a
lack of data, and are now limiting its use in older people.

Harnden said Wednesday's announcement had not been taken
lightly and it had been right to keep using the shot, even if
the advice was now changing.

"Stopping and starting and changing vaccination programmes
is not an easy thing to do, and if you do it, it runs the danger
of losing confidence in that programme," he said.

STILL ON TRACK

Britain is leaning on AstraZeneca for a large portion of its
vaccine supply, with 100 million doses ordered.

But it has also has been rolling out vaccines made by Pfizer
, since December, and Moderna since Wednesday.
Shots made by Johnson & Johnson and Novavax are
also pending regulatory approval in the coming months.

Hancock said that with 40 million Pfizer and 17 million
Moderna vaccines ordered, there was more than enough shots to
cover the 8.5 million people under-30s who needed to be
vaccinated. Healthy under-30s are in the last priority cohort to
be vaccinated, with most not eligible until the summer.

"We feel that we've got enough vaccine supply to be able to
offer (an) alternative vaccine, without delaying the progress of
our immunisations," JCVI's Harnden said, adding Britain was on
track to give a first shot of vaccine to all adults by the end
of July.

"It may slip by a week or two, but no more than that," he
said.

The advice did not change for under-30s who have underlying
conditions and are eligible for shots now, meaning only very few
people who are due to have a shot in the coming days will be
affected by the advice change.

Alison Astles, a pharmacist whose 59-year-old brother died
of a blood clot on the brain on Sunday, encouraged people to
still get their AstraZeneca shots even though it was "very
strongly suggested" his death was due to the shot.

"The sister in me still feels absolutely furious and very
angry that this has happened to my brother... But despite what
has happened to Neil, and the impact on our family, I still
strongly believe that people should go ahead and have the
vaccine," she said.

"Overall, we will save more lives by people having the
vaccine than not."
(Reporting by Alistair Smout, additional reporting by Josephine
Mason; Editing by Andrew Heavens)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.